“Biosimilar SB15 and Aflibercept Equivalent in Neovascular Macular Degeneration Treatment: Clinical Trial Results on Efficacy, Safety, Pharmacokinetics, and Immunogenicity”

https://pubmed.ncbi.nlm.nih.gov/38114333

This clinical trial found that biosimilar SB15 and reference aflibercept have comparable efficacy, safety, pharmacokinetics, and immunogenicity in treating neovascular age-related macular degeneration, and switching from aflibercept to SB15 did not affect these outcomes.